ERBB2 and breast cancer: Moreover, when the triple combination treatment arm was compared to 2D static observed data (Supplementary Figure 1B) and 3DD model simulations for the individual arms (PAC and DAS+EVE), it was found that all three drugs were required to obtain maximum cell killing, demonstrating enhanced efficacy of the treatment combination and its potential application in overcoming resistance to HER2-targeted therapies in BC.